GSK announced a major breakthrough concerning cancer therapy. A drug called Jemperli (dostarlimab) showed impressive results in a phase 2 trial at the Memorial Sloan Kettering Cancer Center (MSK).

Getty Images A new clinical trial shows the immunotherapy drug dostarlimab could eliminate the need for surgery and chemotherapy in certain cancers. The results are a medical breakthrough since ...

The trial sponsored by GSK Plc (NYSE:GSK) assessed the belrestotug + dostarlimab doublet in previously untreated, unresectable, locally advanced, or metastatic PD-L1 high non-small cell lung ...

But in 2024, she published encouraging results from a small study of people with rectal cancer, in which all 42 patients who got the checkpoint inhibitor, dostarlimab, as a monthly infusion became ...

Most study participants were able to avoid operations after taking dostarlimab. A new study in the New England Journal of Medicine suggests that some people with early stage cancers may be able to ...

Dostarlimab offers hope in cancer treatment. Study shows tumour shrinkage in patients with mismatch repair defect. Some rectal cancer patients saw complete tumour disappearance. Maureen Sideris ...

Dostarlimab treatment led to complete clinical responses in 82% of patients with dMMR tumors, avoiding surgery for most. Recurrence-free survival at two years was 92%, with a median follow-up of ...

dostarlimab monotherapy in PD-L1 positive head and neck squamous cell carcinoma. Based on these results, iTeos and GSK have decided to terminate the belrestotug development program and end the ...